-
Just-released results from international trials indicate a potential vaccine, designed to protect against nine HPV strains, might be the next step in cervical cancer protection. In the pivotal Phase III efficacy study, the investigational 9-valent HPV vaccine prevented approximately 97% of cervical, vaginal, and vulvar pre-cancers caused by HPV types 31, 33, 45, 52, and 58.
-
Continuing Warfarin for Pacemaker/ICD Implantation is Safer Than Bridging; Bariatric Surgery Impact on Cholesterol Metabolism; The Do-it-Yourself Diabetes Diagnosis Kit; Low Creatinine Excretion Associated with Mortality in Type 2 Diabetes; Diabetes and Cognitive Function; Benefits of Screening for Lung Cancer with Low-Dose CT
-
-
As a healthcare provider, there are several things you can do to help women lower their risks for gynecologic cancer.
-
-
FHI 360 has launched its Contraceptive Technology Innovation Initiative to develop innovative, long-acting contraceptives.
-
Women seeking emergency contraception (EC) are at high risk of unintended pregnancy.
-
Some 776,000 U.S. residents incur new genital herpes infections annually. There is no cure. Initial, positive results are reported for a therapeutic vaccine candidate for treating genital herpes.
-
The last several years have brought unprecedented attacks on the publicly supported family planning effort in the United States.
-
Can increased use of the copper T intrauterine device (ParaGard IUD, Teva Womens Health, North Wales, PA) for emergency contraception (EC) make an impact on the rate of unplanned pregnancy at your clinic?
